Ozempic's Physical Benefits Don't Extend to Mental Health or Employment, Study Finds

Ozempic and similar GLP-1 medications have proven themselves in the clinic: they lower blood sugar, shed pounds, strengthen the heart. But a new study suggests their power stops at the body's edge. Researchers examining a decade of national health data found little evidence that these drugs improve mental health, employment prospects, marriage stability, or how people rate their own well-being—at least not in ways that show up in measurable outcomes.

Robert Kaestner, an economist at the University of Chicago Harris School of Public Policy, and his colleague Cuiping Schiman set out to answer a question that had largely gone unexamined: Do the physical gains from GLP-1 treatment ripple outward into other parts of life? They analyzed more than ten years of data from the Medical Expenditure Panel Survey, focusing on adults with diabetes between 2012 and 2023. Rather than simply comparing people who took these medications to those who didn't, they tracked the same individuals over time, watching whether their circumstances shifted after they started treatment.

The researchers looked for changes in depression symptoms, psychological distress, self-rated health, employment status, and marital status. At first glance, GLP-1 users appeared different from non-users in some areas—they seemed more likely to be employed and married. But when the researchers zoomed in on individual trajectories, those gaps largely evaporated. The initial differences, it turned out, probably reflected who chose to take the drugs in the first place, not what the drugs actually did. Whether the team examined outcomes after roughly one year of treatment or tracked people over two years, the pattern held: little measurable change in these broader life domains.

Kaestner was careful to note what the study did not prove. The absence of evidence is not evidence of absence. Some effects might be real but subtle—shifts in self-esteem, relationship quality, or daily confidence that don't register as employment gained or lost, marriage entered or dissolved. The measures the researchers used, while important, are blunt instruments. They capture major life events but not the texture of lived experience.

The timing of this research matters. As insurers and government programs weigh whether to expand access to GLP-1 medications beyond diabetes treatment into the broader weight-management market, the question of what these drugs actually deliver has moved from academic curiosity to policy urgency. The medical benefits are settled science. But if policymakers are considering whether to fund these expensive treatments more widely, they need to know whether the physical improvements translate into economic or social gains—whether a person who loses weight and stabilizes their blood sugar also finds work more easily, or feels less depressed, or experiences a stronger marriage.

Kaestner emphasized that the findings do not undermine the established medical value of GLP-1 drugs. For people with diabetes, the clearest benefits remain those already documented in clinical trials: better glycemic control, weight loss, improved cardiovascular outcomes. What remains unknown is whether these medications produce broader social effects in other populations or over longer time horizons. As use expands and more people take these drugs for longer periods, researchers will have fresh opportunities to study whether effects emerge that weren't visible in the diabetes population. For now, the message is measured: these drugs work powerfully on the body. Whether they work on the life built around that body remains an open question.